[1] Adams LA,Sanderson S,Lindor KD,et al.The histological course of nonalcoholic fatty liver disease:a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol,2005,42(1):132-138. [2] Rahimi RS,Landaverde C.Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol,2008,28(2):40-51. [3] Bellentani S,Scaglioni F,Marino M,et al.Epidemiology of non-alcoholic fatty liver disease. Dig Dis,2010,28(1):155-161. [4] 范建高,管又飞. 重视中国特色的高脂血症脂肪肝的研究. 中华肝脏病杂志,2011,19(9):641-642. [5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南(2018年版).实用肝脏病杂志,2018,21(2):177-186. [6] Alberti KG Eckel RH,Grundy SM,et al. Harmonizing the metabolic syndrome:a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart,lung,and blood institute;American heart association;World heart federation;International atherosclerosis society;and International association for the Study of Obesity. Circulation, 2009,120(16):1640-1645. [7] 曹意,王澄,师雯琦,等. 广州市中老年人非酒精性脂肪肝患病率及代谢相关因素分析. 中华流行病学杂志,2015,36(9):958-961. [8] Cheung O,Kapoor A,Puri P,et al.The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology,2007,46(4):1091. [9] Streba LA,Carstea D,Mitrut P,et al.Nonalcoholic fatty liver disease and metabolic syndrome:a concise review. Rom J Morphol Embryol,2008,49(1):13. [10] Sniderman AD,Jungner I,Holme I,et al.Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med,2010,259(5):455-461. [11] Sniderman AD,Furberg CD,Keech A,et al.Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet,2004,16(1):38-38. [12] Elias N,Patterson BW,Schonfeld G.In vivo metabolism of ApoB,ApoA-I,and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene. Arterioscler Thromb Vasc Biol,2000,20(5):1309-1315. [13] Hussain MM,Shi J,Dreizen P.Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res,2003,44(1):22-32. [14] Matthan NR,Welty FK,Barrett PH,et al.Dietary hydrogenated fat increases high-density lipoprotein apoA-I catabolism and decreases low-density lipoprotein apoB-100 catabolism in hypercholesterolemic women. Arterioscler Thromb Vasc Biol,2004,24(6):1092. [15] Ladias JA,Hadzopouloucladaras M,Kardassis D,et al.Transcriptional regulation of human apolipoprotein genes ApoB,ApoCIII,and ApoAII by members of the steroid hormone receptor superfamily HNF-4,ARP-1,EAR-2,and EAR-3. J Biol Chem,1992,267(22):15849. [16] Taghibiglou C,Carpentier A,Van Iderstine SC,et al.Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly,reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster mouse. J Biol Chem,2001,11(5):170-176. [17] Alkhouri N,Tamimi AR,Yerian L,et al.The inflamed liver and atherosclerosis:a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci,2010,55(9):2644-2650. [18] Pacifico L,Cantisani V,Ricci P,et al.Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res,2008,63(4):423-427. [19] Brea A,Mosquera D,Martín E,et al.Nonalcoholic fatty liver sisease is associated with carotid atherosclerosis:A case-control study. Arterioscler Thromb Vasc Biol,2005,25(5):1045-1050. [20] 李旭. 恩替卡韦联合水飞蓟宾葡甲胺治疗慢性乙型肝炎合并NAFLD患者疗效初步研究. 实用肝脏病杂志,2017,20(6):676-679. [21] Amarenco P,Labreuche J,Lavallée P,et al.Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date Meta-analysis. Stroke,2004,35(12):2902-2909. [22] 张宁,赵彩彦. 他汀类药物对肝细胞癌的作用及机制研究进展. 实用肝脏病杂志,2015,18(3):329-332. [23] Violeta B,Joseph K.Treatment of nonalcoholic fatty liver disease:the role of medical,surgical,and endoscopic weight loss.J Clinic Transl Hepatol,2015,3(3):230-231. |